Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Teri Kreisl"'
Autor:
Jennifer Ho, John Ondos, Holly Ning, Sharon Smith, Teri Kreisl, Fabio Iwamoto, Joohee Sul, Lyndon Kim, Kate McNeil, Andra Krauze, Uma Shankavaram, Howard A Fine, Kevin Camphausen
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70745 (2013)
Standard treatment for glioblastoma (GBM) is surgery followed by radiation (RT) and temozolomide (TMZ). While there is variability in survival based on several established prognostic factors, the prognostic utility of other factors such as tumor size
Externí odkaz:
https://doaj.org/article/69828596b33a4444b93260639693074d
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey, Kristina Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V. Ortiz, Eugene F. Douglass, Melissa Accordino, Suzanne Mistretta, Frances Brogan, Jeffrey N. Bruce, Cristina I. Caescu, Richard D. Carvajal, Katherine D. Crew, Guarionex Decastro, Mark Heaney, Brian S. Henick, Dawn L. Hershman, June Y. Hou, Fabio M. Iwamoto, Joseph G. Jurcic, Ravi P. Kiran, Michael D. Kluger, Teri Kreisl, Nicole Lamanna, Andrew B. Lassman, Emerson A. Lim, Gulam A. Manji, Guy M. McKhann, James M. McKiernan, Alfred I. Neugut, Kenneth P. Olive, Todd Rosenblat, Gary K. Schwartz, Catherine A. Shu, Michael B. Sisti, Ana Tergas, Reena M. Vattakalam, Mary Welch, Sven Wenske, Jason D. Wright, Peter Canoll, Hanina Hibshoosh, Kevin Kalinsky, Mahalaxmi Aburi, Peter A. Sims, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Publikováno v:
Cancer Discovery. :OF1-OF22
Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2372be69c8c6242e5877bc9ce0d6bdc4
https://doi.org/10.1158/2159-8290.cd-22-1020
https://doi.org/10.1158/2159-8290.cd-22-1020
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey, Kristina C. Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V. Ortiz, Eugene F. Douglass, Melissa Accordino, Suzanne Mistretta, Frances Brogan, Jeffrey N. Bruce, Cristina I. Caescu, Richard Carvajal, Katherine Crew, Guarionex Decastro, Mark Heaney, Brian Henick, Dawn Hershman, June Hou, Fabio Iwamoto, Joseph Jurcic, Ravi P. Kiran, Michael Kluger, Teri Kreisl, Nicole Lamanna, Andrew Lassman, Emerson Lim, Gulam A. Manji, Guy McKhann, James McKiernan, Alfred I. Neugut, Kenneth Olive, Todd Rosenblat, Gary K. Schwartz, Catherine Shu, Michael Sisti, Ana Tergas, Reena Vattakalam, Mary Welch, Sven Wenske, Jason D. Wright, Hanina Hibshoosh, Kevin M. Kalinsky, Mahalaxmi Aburi, Peter A. Sims, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b58393c179b0e2f8283d6ee880918df
https://doi.org/10.2139/ssrn.4069033
https://doi.org/10.2139/ssrn.4069033
Autor:
Corinne E Griguer, Claudia R Oliva, Christopher S Coffey, Merit E Cudkowicz, Robin A Conwit, Anna L Gudjonsdottir, Dixie J Ecklund, Janel K Fedler, Tina M Neill-Hudson, Louis B Nabors, Melanie Benge, James R Hackney, Marianne Chase, Timothy P Leonard, Toral Patel, Howard Colman, Macarena de la Fuente, Rekha Chaudhary, Karen Marder, Teri Kreisl, Nimish Mohile, Milan G Chheda, Katharine McNeill, Priya Kumthekar, Aclan Dogan, Jan Drappatz, Vinay Puduvalli, Agnes Kowalska, Jerome Graber, Elizabeth Gerstner, Stephen Clark, Michael Salacz, James Markert
Publikováno v:
Neuro-oncology Advances
Background Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a mitochondrial enzyme involved in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee80388673e3937853bea9f5e5b3a0db
http://europepmc.org/articles/PMC8788017
http://europepmc.org/articles/PMC8788017
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey, Kristina C. Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V. Ortiz, Melissa Accordino, Suzanne Mistretta, Frances Brogan, Jeffrey N. Bruce, Cristina I. Caescu, Richard Carvajal, Katherine Crew, Guarionex Decastro, Mark Heaney, Brian Henick, Dawn Hershman, June Hou, Fabio Iwamoto, Joseph Jurcic, Ravi P. Kiran, Michael Kluger, Teri Kreisl, Nicole Lamanna, Andrew Lassman, Emerson Lim, Gulam A. Manji, Guy McKhann, James McKiernan, Alfred Neugut, Kenneth Olive, Todd Rosenblat, Gary K. Schwartz, Catherine Shu, Michael Sisti, Ana Tergas, Reena Vattakalam, Mary Welch, Sven Wenske, Jason D. Wright, Hanina Hibshoosh, Kevin Kalinsky, Mahalaxmi Aburi, Peter A. Sims, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Predicting tumor sensitivity to antineoplastics remains an elusive challenge, with no methods demonstrating predictive power. Joint analysis of tumors—from patients with distinct malignancies who had progressed on multiple lines of therapy—and dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d042b608599fa84e39415b1b49af898
https://doi.org/10.1101/2021.10.03.462951
https://doi.org/10.1101/2021.10.03.462951
Autor:
Veena M. Singh, Robbie Schultz, Melissa Kate Accordino, Deanna Fisher, Margaux Wooster, Julia E. McGuinness, Lan Huynh, Kathleen Fenn, Aya Haggiagi, Teri Kreisl, Julie Ann Mayer, Fabio M. Iwamoto, Andrew B. Lassman, Edgar V. Sales, Meghna S. Trivedi, Katherine D. Crew, Mary Welch, Shing Lee, Kevin Kalinsky, Lauren Franks, Dawn L. Hershman, David Cieremans
Introduction: Diagnosis of leptomeningeal metastasis (LM) is limited by low sensitivity of cerebrospinal fluid (CSF) cytopathology. Detecting circulating tumor cells (CTCs) in CSF might be more sensitive. We evaluated if TargetSelector™ (TS), a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69da7cc716c574bcab3e4db9d540a32d
https://doi.org/10.21203/rs.3.rs-206232/v1
https://doi.org/10.21203/rs.3.rs-206232/v1
Autor:
Edward B. Garon, Andrea Ardizzoni, Fabrice Barlesi, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Dariusz Kowalski, Shun Lu, David R. Spigel, Michael Thomas, James Chih-Hsin Yang, Sabine Turri, Wen Zhou, Teri Kreisl, Luis Paz-Ares
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA039-LBA039
Background: In the CANTOS study, canakinumab (selective interleukin 1β inhibitor) treatment was associated with reduced incidence and mortality from non-small cell lung cancer (NSCLC) in stable post–myocardial infarction patients with elevated hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a1b8b92829aee6fb0ed033251b8cc6a
https://doi.org/10.1158/1535-7163.targ-21-lba039
https://doi.org/10.1158/1535-7163.targ-21-lba039
Autor:
Yazmin Odia, John A. Butman, Fabio M. Iwamoto, Howard A. Fine, Joanna H. Shih, Joohee Sul, Teri Kreisl
Publikováno v:
CNS Oncology. 5:59-67
Aim: A Phase II trial of bevacizumab plus tandutinib. Methods: We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for a trial of bevacizumab plus tandutinib. Median age was 55 and 71% were male. Treatment consisted of tandutinib 500 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500f06d8c906c9e323ce31711c576b82
https://doi.org/10.2217/cns-2015-0010
https://doi.org/10.2217/cns-2015-0010
Autor:
Teri Kreisl, Fabio M. Iwamoto, Elizabeth J. Buss, Oscar Padilla, Aya Haggiagi, Angela Lignelli-Dipple, Marissa Barbaro, Laura Donovan, Carl D. Elliston, Tony J. C. Wang, Jeffrey N. Bruce, Adela Joanta-Gomez, Mary Welch, Peter Canoll, Peter Pan, Andrew B. Lassman
Publikováno v:
Neuro Oncol
BACKGROUND Late-delayed radiation effects appear 6 months to years following radiotherapy. We characterize a species of small enhancing lesions in the late-delayed phase of post-radiotherapy that are distinct from the classic descriptions of radiatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de8347d3a483de8c6f0683325e7d98e
https://doi.org/10.1093/neuonc/noaa215.680
https://doi.org/10.1093/neuonc/noaa215.680
Autor:
Melissa Kate Accordino, Katherine D. Crew, Shing Mirn Lee, Teri Kreisl, Kevin Kalinsky, David Cieremans, Andrew B. Lassman, Veena M. Singh, Lan Huynh, Kathleen Fenn, Dawn L. Hershman, Meghna S. Trivedi, Fabio M. Iwamoto, Julie Ann Mayer, Deanna Fisher, Robbie Schultz, Edgar V. Sales
Publikováno v:
Journal of Clinical Oncology. 38:3567-3567
3567 Background: Diagnosis of LM from solid tumors can be challenging. The TargetSelector (TS) CTC detection assay has demonstrated highly specific and sensitive CTC capture both for epithelial (CK+) and non-epithelial (CK-) subsets. The assay utiliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5575376a81b408c708f5338aa740eb96
https://doi.org/10.1200/jco.2020.38.15_suppl.3567
https://doi.org/10.1200/jco.2020.38.15_suppl.3567